

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF  
ATTORNEY WITH  
NEW POWER OF ATTORNEY  
AND  
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/713,749
Filing Date	November 14, 2000
First Named Inventor	Daniel M. Lafontaine
Art Unit	3739
Examiner Name	Ahmed M. Farah
Attorney Docket Number	1001.2642105

**I hereby revoke all previous powers of attorney given in the above-identified application.**

☐ A Power of Attorney is submitted herewith.

**OR**

☒ I hereby appoint the practitioners associated with the Customer Number:

11050

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with  
Customer Number:

11050

**OR**

☐ Firm or  
Individual Name

Address

City

State

Zip

Country

Telephone

Email

**I am the:**

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature

Name

Jeffrey Cook, Patent Attorney for BOSTON SCIENTIFIC SCIMED, INC.

Date

NOV 18, 2010

Telephone

763-494-1700

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ \*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE  
REGARDING CERTAIN PATENT MATTERS  
EFFECTIVE THROUGH: December 31, 2011**

\*\*\*\*\*


I, Timothy A. Pratt, as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Action Medical, Inc.; Adam Acquisition 2001 Inc.; Advanced Biomics Corporation; Advanced Stent Technologies, Inc.; Advanced Stent Technologies, LLC; ABE, Inc.; AMS-Medivest S.A.; Angionedics Incorporated; Ashtarkh, Inc.; BEI Medical Systems; BEI Medical Systems Company, Inc.; BEI Medical Systems International, Inc.; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Glens Falls Corp.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Miami Corporation; Boston Scientific Mountain View Corporation; Boston Scientific Neuromodulation Corporation; Boston Scientific Santa Rosa Corp.; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Boston Scientific Technology Inc.; Boston Scientific Wayne Corporation; Broadway Acquisition Corporation; BSC Technology, Inc.; Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; CardioGene Therapeutics, Inc.; Cardiothoracic Systems, Inc.; Cardiovascular Imaging Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Celsion Corporation; Charger Acquisition Corp.; Claude Acquisition Corporation; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CRV Acquisition Corp.; CryoCor, Inc.; CryoVascular Systems, Inc.; Embolix Protection, Inc.; Embryo Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation; Guidant Foundation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technology Inc.; Heart Technology Manufacturing, Inc.; ID Acquisition Corp.; Incept LLC; Inflow Dynamics Inc.; Internedics, Inc.; Interventional Technologies, Inc.; Interventional Therapeutics Corporation; Interventional Therapeutics Int'l; KPS Acquisition Corporation; Labcoat Limited; Laboratoires Corvita S.A.R.L.; Mansfield Scientific, Inc.; Meadox Medicals, Inc.; Meadox Technology, Inc.; Medi-Tech Incorporation; Merger Sub, Inc.; Microvasive, Inc.; MW Medical, Inc.; NAMIC Caribe, Inc.; NAMIC Bireum Limited; NAMIC International, Inc.; NAMIC U.S.A. Corporation; Nemo I Acquisition, Inc.; Neuro Interventions, Inc.; New Heart Technology, Inc.; Nilo Holding, S.A.; North American Instrument Corporation; Novoste Puerto Rico Inc.; Odyssey Technologies, Inc.; Origin Medical Systems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quantum Medical Corporation; Radio Therapeutics Corporation; Remon Medical Technologies, Ltd.; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider (USA) Inc.; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider (NAMIC); Schneider-Shiley (USA) Inc.; Scimed Life Systems, Inc.; SciMed Technology, Inc.; Scimed, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Surgimed, Inc.; Synbiotic Corporation; Target Therapeutics, Inc.; TriVascular 2, Inc.; TriVascular, Inc.; Van-Tec, Inc.; and Vesica Medical Inc.

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Poissant ..... Reg. No. 56,871  
Alana Bergman ..... Reg. No. 47,420  
James R. Chiapetta ..... Reg. No. 39,634  
Sara J. Citrowske ..... Reg. No. 55,076  
Jeffrey P. Cook ..... Reg. No. 48,649  
Luke R. Dohmen ..... Reg. No. 36,783  
Peter J. Cafner ..... Reg. No. 36,517  
Lori J. Heinrichs ..... Reg. No. 43,667  
Albert K. Kaur ..... Reg. No. 40,672

Philip H. Lee ..... Reg. No. 50,645  
Kurt W. Lockwood ..... Reg. No. 40,704  
Jeffrey Z. Mann ..... Reg. No. 51,994  
Steven A. McAuley ..... Reg. No. 46,084  
Todd P. Messal ..... Reg. No. 42,883  
Tyler L. Nasiedlak ..... Reg. No. 40,099  
Peter Nigrelli ..... Reg. No. 66,461  
William J. Shaw ..... Reg. No. 43,111  
Kimberly S. Zillig ..... Reg. No. 46,346


  
Timothy A. Pratt, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary

01/15/11  
Date

COMMONWEALTH OF MASSACHUSETTS )

COUNTY OF MIDDLESEX ) ss.

On this 13th day of January, 2011, before me personally appeared Timothy A. Pratt to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

  
Notary Public

